GSK's Paxil plant cited in warning letter

Share this article:
GSK misses on late-stage CV drug
GSK’s Paxil plant cited in warning letter

GlaxoSmithKline got some unwelcome attention from the FDA inspectors: a March 27 warning letter about unacceptable manufacturing and communications at a Cork, Ireland, manufacturing site where it found contamination issues. The letter notes that this is not the first time the regulator has asked about this plant, and that the firm's initial response "lacks sufficient corrective actions."

Dublin-based news website RTE reports that the plant made active ingredients for the anti-depressant Paxil and has since recalled batches of the drug.

The FDA notes that failure to provide an adequate response and fixes may prompt the US agency to ban materials produced at this site, which uses the company name SmithKline Beecham.

The FDA's list of grievances includes accusations that the drugmaker distributed products even after it knew items could have been contaminated.

The FDA noted that although GSK's own communications requirements indicate the company has to tell customers about possible deviations, like the potentially contaminated product, it failed to do so at the time. “We are concerned that your firm does not consider the entry of pharmaceutical waste streams into your manufacturing process a significant deviation with a potential quality impact,” the agency wrote.

The FDA also calls out the manufacturer for ignoring red flags that exist to indicate contamination. It noted that two gas chromatic analyses—a test that can spot problems—“show large peaks... as well as small but detectable levels of at least 10 other contaminants,” but GSK did nothing about warnings. The FDA also says the company response does not explain why its analysts did not see these contamination signals.

Additional concerns include the site's failure to use consecutive testing batches.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...